Search

• ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

  Media

  The Phase 3 TANGO study is the 3rd trial to provide long-term evidence for Dovato reinforcing its use as a viable switch for people with HIV

  https://www.gsk.com/en-gb/media/press-releases/viiv-presents-three-year-switch-data-for-dovato/

  First published: 29 September 2021

• ViiV Healthcare presents long-term switch data for Dovato demonstrating non-inferior efficacy in adults with HIV-1 and zero cases of virologic failure versus continuation of a 3-drug TAF-based regimen

  Media

  The TANGO 96-week data presented at HIV Glasgow 2020 also confirm Dovato’s well-established safety and tolerability profile

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-long-term-switch-data-for-dovato/

  First published: 08 October 2020

• Dovato (dolutegravir/lamivudine), the once-daily, single-pill, 2-drug regimen for the treatment of HIV-1 infection, granted marketing approval by Japan Ministry of Health, Labour and Welfare

  Media

  ViiV Healthcare, the global specialist HIV company announced that it has obtained approval of Dovato.

  https://www.gsk.com/en-gb/media/press-releases/dovato-dolutegravirlamivudine-granted-marketing-approval-by-japan-ministry-of-health-labour-and-welfare/

  First published: 15 January 2020

• ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1

  Media

  Largest head-to-head randomised clinical trial between DTG/3TC and BIC/FTC/TAF showed DTG/3TC demonstrated non-inferior efficacy

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-data-demonstrating-2-drug-regimen-dovato-is-as-effective-as-3-drug-regimen-biktarvy-for-maintenance-therapy-of-hiv-1/

  First published: 23 July 2024

• ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs

  Media

  ViiV Healthcare today presented 48-week data from the SALSA study at the International AIDS Society Conference 2021

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-data-from-second-dovato-switch-study/

  First published: 17 July 2021

• ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024

  Media

  The presentation is one of 25 abstracts evaluating the company’s portfolio of marketed HIV treatment and prevention options.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-announce-data-from-largest-head-to-head-randomised-clinical-trial-for-2-drug-regimen-dovato-at-aids-2024/

  First published: 15 July 2024

• ViiV Healthcare receives EU Marketing Authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection

  Media

  Dovato achieved non-inferior efficacy compared to a dolutegravir-based, three-drug regimen through 48 weeks.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-dovato-dolutegravirlamivudine-a-new-once-daily-single-pill-two-drug-regimen-for-the-treatment-of-hiv-1-infection/

  First published: 03 July 2019

• US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults

  Media

  Dovato strengthens ViiV Healthcare’s industry-leading portfolio of innovative treatment approaches for people living with HIV.

  https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-viiv-healthcare-s-dovato-dolutegravirlamivudine-the-first-once-daily-single-tablet-two-drug-regimen-for-treatment-naïve-hiv-1-adults/

  First published: 08 April 2019

• ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection

  Media

  Recommendation based on GEMINI 1 & 2 studies which demonstrated non-inferior efficacy.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-chmp-positive-opinion-for-dovato-dolutegravirlamivudine-as-a-once-daily-single-pill-two-drug-regimen-for-the-treatment-of-hiv-infection/

  First published: 26 April 2019

• ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress

  Media

  Data presented will reinforce the potential to shift the treatment paradigm to 2-drug regimens (2DRs) for people living with HIV

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-long-term-safety-and-efficacy-data-for-2-drug-regimen/

  First published: 30 September 2020